Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CR4056 (6-(1H-imidazol-1-yl)-2-phenylquinazoline) 是一种特异性 MAO-A 抑制剂,IC50 为 202.7 nM,是 I2-咪唑啉受体的配体,IC50 为 596 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 2,920 | 现货 | ||
10 mg | ¥ 4,320 | 现货 | ||
25 mg | ¥ 6,880 | 现货 | ||
50 mg | ¥ 9,330 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
500 mg | ¥ 25,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,980 | 现货 |
产品描述 | CR4056 (6-(1H-imidazol-1-yl)-2-phenylquinazoline) is a selective inhibitor of MAO-A with IC50 of 202.7 nM and a ligand of I2-imidazoline receptor with IC50 of 596 nM. |
靶点活性 | MAO-A:202.7 nM, I2R:596 nM |
体外活性 | The co-treatment of CR4056 (3-30 μM) with Bortezomib does not induce any significant difference in cell survival compared with BTZ-treated cells, either in H929 or in RPMI 8226 myeloma cells[1]. |
体内活性 | CR4056 (30 mg/kg) completely reverses the effect of capsaicin, increasing the paw withdrawal threshold (PWT) to 239. CR4056 obviously increases the mechanical withdrawal thresholds of both ipsilateral (F[4, 30]=19.97) and contralateral (F[4, 30]=31.58) hind paws. CR4056 dose-dependently reduces mechanical hyperalgesia with ED50 of 5.8 mg/kg. CR4056 dose-dependently decreases streptozotocin (STZ)-induced diabetic pain in rats (F[4, 35]=31.27). CR4056 (20 mg/kg; oral) increases endogenous norepinephrine (NE) levels by 68.2% in the parieto-occipital cortex. CR4056 (20 mg/kg; p.o.) obviously increases NE levels both in the cerebral cortex (63.1%) and in the lumbar spinal cord (51.3%). CR4056 (10 mg/kg) and Piroxicam (10 mg/kg) obviously reverse the decrease in the withdrawal threshold caused by Capsaicin[2]. |
别名 | 6-(1H-imidazol-1-yl)-2-phenylquinazoline |
分子量 | 272.3 |
分子式 | C17H12N4 |
CAS No. | 1004997-71-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (91.81 mM), Sonication is recommended.
H2O: < 0.1 mg/mL (insoluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.6724 mL | 18.3621 mL | 36.7242 mL | 91.8105 mL |
5 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL | 18.3621 mL | |
10 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL | 9.1811 mL | |
20 mM | 0.1836 mL | 0.9181 mL | 1.8362 mL | 4.5905 mL | |
50 mM | 0.0734 mL | 0.3672 mL | 0.7345 mL | 1.8362 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CR4056 1004997-71-0 Metabolism Neuroscience MAO Imidazoline Receptor 6-(1H-imidazol-1-yl)-2-phenylquinazoline CR 4056 CR-4056 Inhibitor inhibitor inhibit